Entheon Biomedical Corp.

Equities

ENBI

CA29383X2023

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange 03:43:20 2024-04-15 pm EDT 5-day change 1st Jan Change
0.14 CAD 0.00% Intraday chart for Entheon Biomedical Corp. +27.27% +40.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding CI
Entheon Biomedical Corp. Reports Earnings Results for the Full Year Ended November 30, 2023 CI
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023 CI
Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science Officer CI
Entheon Biomedical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023 CI
Heading Health Inc. announced that it has received $4.5 million in funding from a group of investors CI
Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 28, 2023 CI
Entheon Biomedical Corp. Announces Termination of Consulting Agreement with Cybin CI
Entheon Biomedical Corp. Auditor Raises 'Going Concern' Doubt CI
Entheon Biomedical Corp. Announces Resignation of Ruth Chun as Director CI
Entheon Biomedical Corp. Announces CFO Changes CI
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022 CI
Entheon Biomedical Corp. Closes Patient Enrolment in its Clinical Research Study EBIQ-101 CI
Entheon Biomedical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022 CI
Entheon Biomedical Corp. cancelled the transaction announced on April 5, 2022 CI
Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 28, 2022 CI
Entheon Biomedical Corp. announced that it expects to receive CAD 3 million in funding CI
Entheon Biomedical Corp. Reports Earnings Results for the Full Year Ended November 30, 2021 CI
Entheon Biomedical Corp. Auditor Raises 'Going Concern' Doubt CI
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel, New Clinical Research Platform MT
Entheon Biomedical Corp. Announces Enrollment in Phase 1 Study of DMT CI
Entheon Biomedical Corp. Announces EBIQ-101 First-Patient Dose CI
Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study CI
Entheon Biomedical Corp. Announces the Approval of DMT Clinical Trial CI
Entheon Biomedical Corp. Announces the Submission of the Regulatory Package for Its Upcoming Phase 1 Clinical Trial CI
Chart Entheon Biomedical Corp.
More charts
Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.
More about the company
  1. Stock Market
  2. Equities
  3. ENBI Stock
  4. News Entheon Biomedical Corp.
  5. Entheon Biomedical : Up 3.3% after Reporting Listing on OTCQB Venture Market